
## Brian F Gage

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10240124/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Different Risks of Hemorrhage in Patients with Elevated International Normalized Ratio from Chronic Liver Disease Versus Warfarin Therapy: A Populationâ€based Retrospective Cohort Study. Journal of Thrombosis and Haemostasis, 2022, , .	3.8	2
2	Standardization of risk prediction model reporting in cancerâ€associated thrombosis: Communication from the ISTHÂSSC subcommittee on hemostasis and malignancy. Journal of Thrombosis and Haemostasis, 2022, 20, 1920-1927.	3.8	3
3	Improving Followâ€up Attendance for Discharged Emergency Care Patients Using Automated Phone System to Selfâ€schedule: A Randomized Controlled Trial. Academic Emergency Medicine, 2021, 28, 197-205.	1.8	2
4	Predictors of longâ€ŧerm opioid use and opioid use disorder among construction workers: Analysis of claims data. American Journal of Industrial Medicine, 2021, 64, 48-57.	2.1	8
5	Lung transplant outcomes are influenced by severity of neutropenia and granulocyte colony-stimulating factor treatment. American Journal of Transplantation, 2020, 20, 250-261.	4.7	22
6	Splanchnic vein thrombosis predicts worse survival in patients with advanced pancreatic cancer. Thrombosis Research, 2020, 185, 125-131.	1.7	17
7	Statins Reduce Mortality in Multiple Myeloma: A Population-Based US Study. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e937-e943.	0.4	6
8	Venous thromboembolism in multiple myeloma is associated with increased mortality. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1203-1210.	2.3	19
9	Maximal dose-response of vitamin-K2 (menaquinone-4) on undercarboxylated osteocalcin in women with osteoporosis. International Journal for Vitamin and Nutrition Research, 2020, 90, 42-48.	1.5	8
10	Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index. Journal of Visualized Experiments, 2020, , .	0.3	8
11	Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. American Journal of Hematology, 2019, 94, 1176-1184.	4.1	112
12	Warfarin-Induced Fractures in Atrial Fibrillation?. Journal of the American College of Cardiology, 2019, 74, 2159-2161.	2.8	8
13	Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty. JAMA - Journal of the American Medical Association, 2019, 322, 834.	7.4	9
14	Assessment of ICDâ€10â€CM code assignment validity for case finding of outpatient anticoagulantâ€related bleeding among Medicare beneficiaries. Pharmacoepidemiology and Drug Safety, 2019, 28, 951-964.	1.9	17
15	Predictive value of the present-on-admission indicator for hospital-associated hemorrhage. Thrombosis Research, 2019, 180, 20-24.	1.7	2
16	Reply. Journal of the American College of Cardiology, 2019, 73, 1873-1874.	2.8	0
17	The Association of Fever and Antipyretic Medication With Outcomes in Mechanically Ventilated Patients: A Cohort Study. Shock, 2019, 52, 152-159.	2.1	12
18	TEG Platelet Mapping and Impedance Aggregometry to Predict Platelet Transfusion During Cardiopulmonary Bypass in Pediatric Patients. Frontiers in Pediatrics, 2019, 7, 509.	1.9	12

#	Article	IF	CITATIONS
19	Factors Associated With Clinical Deterioration Among Patients Hospitalized on the Wards at a Tertiary Cancer Hospital. Journal of Oncology Practice, 2019, 15, e652-e665.	2.5	15
20	Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug–Associated Thrombosis Among Patients With Multiple Myeloma. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 840-847.	4.9	101
21	Postoperative Myocardial Injury and Inflammation Is Not Blunted by a Trial of Atorvastatin in Orthopedic Surgery Patients. HSS Journal, 2018, 14, 67-76.	1.7	4
22	Stroke Prediction Rules in AtrialÂFibrillation. Journal of the American College of Cardiology, 2018, 71, 133-134.	2.8	3
23	Genotype vs Clinically Guided Dosing of Warfarin to Prevent Adverse Events—Reply. JAMA - Journal of the American Medical Association, 2018, 319, 1279.	7.4	0
24	Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring. Journal of the American College of Cardiology, 2018, 72, 3233-3242.	2.8	201
25	Improving Prediction of Postoperative Myocardial Infarction With High-Sensitivity Cardiac Troponin T and NT-proBNP. Anesthesia and Analgesia, 2017, 124, 398-405.	2.2	51
26	Reply to S. Suissa et al. Journal of Clinical Oncology, 2017, 35, 1378-1379.	1.6	0
27	The Reply. American Journal of Medicine, 2017, 130, e115.	1.5	0
28	Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty. JAMA - Journal of the American Medical Association, 2017, 318, 1115.	7.4	198
29	High-Sensitivity Cardiac Troponin T Improves the Diagnosis of Perioperative MI. Anesthesia and Analgesia, 2017, 125, 1455-1462.	2.2	21
30	Interview about the GIFT Trial, Pharmacogenetics, and Warfarin. Pharmacogenomics, 2017, 18, 1379-1380.	1.3	1
31	Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: AÂMeta-Analysis. Journal of Arthroplasty, 2017, 32, 645-652.	3.1	53
32	Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices. Circulation: Heart Failure, 2016, 9,	3.9	86
33	Incidence of Platelet Dysfunction by Thromboelastography–Platelet Mapping in Children Supported with ECMO: A Pilot Retrospective Study. Frontiers in Pediatrics, 2016, 3, 116.	1.9	59
34	Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System. American Heart Journal, 2016, 179, 186-191.	2.7	15
35	Accuracy of Wearable Cameras to Track Social Interactions in Stroke Survivors. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 2907-2910.	1.6	7
36	Statins Are Associated With Reduced Mortality in Multiple Myeloma. Journal of Clinical Oncology, 2016, 34, 4008-4014.	1.6	76

Brian F Gage

#	Article	IF	CITATIONS
37	A systematic analysis and comparison of warfarin initiation strategies. Pharmacogenetics and Genomics, 2016, 26, 445-452.	1.5	5
38	A Tool to Assess Risk of De Novo Opioid Abuse or Dependence. American Journal of Medicine, 2016, 129, 699-705.e4.	1.5	52
39	Application of a Validated Predictive Model for Venous Thromboembolism in Cancer to Patients with Multiple Myeloma. Blood, 2016, 128, 534-534.	1.4	0
40	Risk model for estimating the 1-year risk of deferred lesion intervention following deferred revascularization after fractional flow reserve assessment. European Heart Journal, 2015, 36, 509-515.	2.2	36
41	Clinical Outcomes With Use ofÂErythropoiesis Stimulating Agents inÂPatients WithÂtheÂHeartMate II LeftÂVentricular Assist Device. JACC: Heart Failure, 2015, 3, 146-153.	4.1	25
42	Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation. Journal of General Internal Medicine, 2015, 30, 777-782.	2.6	8
43	Effectiveness and safety of expanded perioperative thromboprophylaxis in complex gynecologic surgery. Gynecologic Oncology, 2015, 138, 501-506.	1.4	31
44	Prognostic utility of novel biomarkers of cardiovascular stress in patients with aortic stenosis undergoing valve replacement. Heart, 2015, 101, 1382-1388.	2.9	90
45	Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data. Thrombosis Research, 2015, 135, 616-620.	1.7	75
46	Clinical Benefit of American College of Chest Physicians Versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation. Journal of General Internal Medicine, 2015, 30, 1405-1405.	2.6	1
47	Metformin Therapy and Survival in Multiple Myeloma Among US Veterans with Diabetes Mellitus. Blood, 2015, 126, 4502-4502.	1.4	0
48	Statin Therapy Improves Multiple Myeloma (MM) Specific Surviva. Blood, 2015, 126, 879-879.	1.4	0
49	Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics, 2014, 15, 1973-1983.	1.3	50
50	Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thrombosis and Haemostasis, 2014, 111, 88-93.	3.4	120
51	Letter in response to "Use of preoperative cardiac troponin T to identify patients at risk for acute myocardial infraction and long-term mortality after major noncardiac surgery― American Heart Journal, 2014, 167, e7.	2.7	0
52	Risk factors for inpatient venous thromboembolism despite thromboprophylaxis. Thrombosis Research, 2014, 133, 25-29.	1.7	42
53	In Reply. Anesthesiology, 2014, 120, 515-516.	2.5	0
54	Venous Thromboembolism Is Associated with Increased Mortality in Patients with Multiple Myeloma. Blood, 2014, 124, 2176-2176.	1.4	1

#	Article	IF	CITATIONS
55	A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing. New England Journal of Medicine, 2013, 369, 2283-2293.	27.0	660
56	Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. American Heart Journal, 2013, 166, 435-441.e2.	2.7	15
57	The Analysis of Bleeding Risk–Prediction Scores Should Include All Major Bleeds. Journal of the American College of Cardiology, 2013, 61, 481-482.	2.8	1
58	Top practice-changing articles over the last two years. Journal of Thrombosis and Thrombolysis, 2013, 35, 325-332.	2.1	1
59	High-sensitivity cardiac troponin T in prediction and diagnosis of myocardial infarction and long-term mortality after noncardiac surgery. American Heart Journal, 2013, 166, 325-332.e1.	2.7	142
60	Influence of Nitrous Oxide Anesthesia, B-Vitamins, and <i>MTHFR</i> Gene Polymorphisms on Perioperative Cardiac Events. Anesthesiology, 2013, 119, 19-28.	2.5	34
61	Effects of Phosphodiesterase Type 5 Inhibition on Systemic and Pulmonary Hemodynamics and Ventricular Function in Patients With Severe Symptomatic Aortic Stenosis. Circulation, 2012, 125, 2353-2362.	1.6	66
62	Admission International Normalized Ratio Levels, Early Treatment Strategies, and Major Bleeding Risk Among Non–ST-Segment–Elevation Myocardial Infarction Patients on Home Warfarin Therapy. Circulation, 2012, 125, 1414-1423.	1.6	17
63	Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thrombosis and Haemostasis, 2012, 107, 232-240.	3.4	62
64	Risk Factors for Inpatient Acute Venous Thromboembolism (VTE) Despite Thromboprophylaxis Blood, 2012, 120, 2248-2248.	1.4	0
65	Higher Doses of Prophylactic Anticoagulation Is More Effective in Preventing Venous Thromboembolism in Morbidly Obese Inpatients Blood, 2012, 120, 2268-2268.	1.4	0
66	Genetic Warfarin Dosing. Journal of the American College of Cardiology, 2011, 57, 612-618.	2.8	123
67	Physician and Nurse Acceptance of Technicians to Screen for Geriatric Syndromes in the Emergency Department. Western Journal of Emergency Medicine, 2011, 12, 489-495.	1.1	55
68	Cost of dabigatran for atrial fibrillation. BMJ: British Medical Journal, 2011, 343, d6980-d6980.	2.3	8
69	Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation. Circulation, 2011, 123, 2562-2570.	1.6	299
70	Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood, 2010, 115, 3827-3834.	1.4	331
71	Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials, 2010, 11, 108.	1.6	79
72	Validation of claimsâ€based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commerciallyâ€insured population. Pharmacoepidemiology and Drug Safety, 2010, 19, 596-603.	1.9	156

#	Article	IF	CITATIONS
73	Gamma-glutamyl carboxylase and its influence on warfarin dose. Thrombosis and Haemostasis, 2010, 104, 750-754.	3.4	53
74	Cost-Effectiveness of Outpatient Cardiac Monitoring to Detect Atrial Fibrillation After Ischemic Stroke, 2010, 41, 1514-1520.	2.0	76
75	Warfarin Genotyping Reduces Hospitalization Rates. Journal of the American College of Cardiology, 2010, 55, 2804-2812.	2.8	327
76	Pediatric warfarin practice and pharmacogenetic testing. Thrombosis Research, 2010, 126, e144-e146.	1.7	9
77	Can We Rely on RE-LY?. New England Journal of Medicine, 2009, 361, 1200-1202.	27.0	66
78	Interactive Modeling for Ongoing Utility of Pharmacogenetic Diagnostic Testing: Application for Warfarin Therapy. Clinical Chemistry, 2009, 55, 1861-1868.	3.2	39
79	Baseline Risk of Major Bleeding in Non–ST-Segment–Elevation Myocardial Infarction. Circulation, 2009, 119, 1873-1882.	1.6	876
80	Anemia: An independent predictor of death and hospitalizations among elderly patients with atrial fibrillation. American Heart Journal, 2009, 157, 1057-1063.	2.7	27
81	Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation. Annals of Internal Medicine, 2009, 150, 73.	3.9	259
82	Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. Journal of Thrombosis and Thrombolysis, 2008, 25, 45-51.	2.1	216
83	Couma-Gen: implications for future randomized trials of pharmacogenetic-based warfarin therapy. Personalized Medicine, 2008, 5, 163-168.	1.5	3
84	Performance of Commercial Platforms for Rapid Genotyping of Polymorphisms Affecting Warfarin Dose. American Journal of Clinical Pathology, 2008, 129, 876-883.	0.7	74
85	CYP4F2 genetic variant alters required warfarin dose. Blood, 2008, 111, 4106-4112.	1.4	471
86	Can Patients at Elevated Risk of Stroke Treated With Anticoagulants Be Further Risk Stratified?. Stroke, 2007, 38, 2459-2463.	2.0	68
87	Anemia Does Not Predict Mortality in Elderly Patients With Heart Failure. The American Journal of Geriatric Cardiology, 2007, 16, 92-96.	0.6	9
88	An Invasive Strategy Is Associated With Decreased Mortality in Patients 80 Years and Older With Acute Myocardial Infarction. The American Journal of Geriatric Cardiology, 2007, 16, 84-91.	0.6	2
89	Optimal Initial Dose Adjustment of Warfarin in Orthopedic Patients. Annals of Pharmacotherapy, 2007, 41, 1798-1804.	1.9	27
90	Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood, 2007, 110, 1511-1515.	1.4	164

#	Article	IF	CITATIONS
91	Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). American Heart Journal, 2006, 151, 713-719.	2.7	890
92	Is primary care ready for pharmacogenetics?. Pharmacogenomics, 2006, 7, 1-3.	1.3	6
93	Pharmacogenetics-Based Coumarin Therapy. Hematology American Society of Hematology Education Program, 2006, 2006, 467-473.	2.5	58
94	Risk of Osteoporotic Fracture in Elderly Patients Taking Warfarin. Archives of Internal Medicine, 2006, 166, 241.	3.8	209
95	The Association of Warfarin Use With Osteoporotic Fracture in Elderly Patients With Atrial Fibrillation—Reply. Archives of Internal Medicine, 2006, 166, 1525.	3.8	0
96	Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial Fibrillation. Stroke, 2006, 37, 1070-1074.	2.0	273
97	Accuracy of ICD-9-CM Codes for Identifying Cardiovascular and Stroke Risk Factors. Medical Care, 2005, 43, 480-485.	2.4	649
98	Comorbidity Indices to Predict Mortality From Medicare Data. Medical Care, 2005, 43, 1073-1077.	2.4	68
99	Simplified peak power reserve in patients with an implantable cardioverter-defibrillator and advanced heart failure. American Journal of Cardiology, 2005, 95, 286-288.	1.6	0
100	Use of EPO in Critically Ill Patients With Acute Renal Failure Requiring Renal Replacement Therapy. American Journal of Kidney Diseases, 2005, 46, 791-798.	1.9	25
101	Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thrombosis and Haemostasis, 2005, 93, 700-705.	3.4	176
102	Preference-Based Antithrombotic Therapy in Atrial Fibrillation: Implications for Clinical Decision Making. Medical Decision Making, 2005, 25, 548-559.	2.4	67
103	Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2005, 293, 699.	7.4	138
104	Effect of <i>VKORC1</i> Haplotypes on Transcriptional Regulation and Warfarin Dose. New England Journal of Medicine, 2005, 352, 2285-2293.	27.0	1,348
105	Reliability for Grading Acute Rejection and Airway Inflammation After Lung Transplantation. Journal of Heart and Lung Transplantation, 2005, 24, 652-657.	0.6	54
106	Pharmacology and pharmacogenetics of warfarin and other coumarins when used with supplements. Thrombosis Research, 2005, 117, 55-59.	1.7	14
107	Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. American Journal of Medicine, 2005, 118, 612-617.	1.5	294
108	Implantable cardioverter-defibrillator therapy improves long-term survival in patients with unexplained syncope, cardiomyopathy, and a negative electrophysiologic study. Heart Rhythm, 2005, 2, 367-373.	0.7	19

#	Article	IF	CITATIONS
109	The pharmacogenetics of coumarin therapy. Pharmacogenomics, 2005, 6, 503-513.	1.3	86
110	Effect of warfarin nonadherence on control of the International Normalized Ratio. American Journal of Health-System Pharmacy, 2004, 61, 1258-1264.	1.0	75
111	Selecting Patients With Atrial Fibrillation for Anticoagulation. Circulation, 2004, 110, 2287-2292.	1.6	728
112	Cost-Effectiveness of Extending Medicare Coverage of Immunosuppressive Medications to the Life of a Kidney Transplant. American Journal of Transplantation, 2004, 4, 1703-1708.	4.7	90
113	Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thrombosis and Haemostasis, 2004, 91, 87-94.	3.4	308
114	The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis. American Journal of Medicine, 2004, 116, 451-459.	1.5	28
115	Yield of surveillance bronchoscopy for acute rejection and lymphocytic bronchitis/bronchiolitis after lung transplantation. Journal of Heart and Lung Transplantation, 2004, 23, 1396-1404.	0.6	48
116	Use of pharmacogenetics to guide warfarin therapy. Drugs of Today, 2004, 40, 247.	2.4	7
117	Randomized Trial of Warfarin Nomograms. Annals of Internal Medicine, 2004, 140, 489.	3.9	2
118	Pharmacogenetics and Anticoagulant Therapy. Journal of Thrombosis and Thrombolysis, 2003, 16, 73-78.	2.1	24
119	Outpatient treatment of acute venous thromboembolic disease. Clinics in Chest Medicine, 2003, 24, 49-61.	2.1	9
120	Perioperative reduction of the warfarin dose. American Journal of Medicine, 2003, 115, 741-742.	1.5	5
121	Predictors of mortality in younger and older patients with heart failure and preserved or reduced left ventricular ejection fraction. American Heart Journal, 2003, 146, 286-290.	2.7	58
122	Costâ€ <b>S</b> avings Analysis of Using a Portable Coagulometer for Monitoring Homebound Elderly Patients Taking Warfarin. The American Journal of Geriatric Cardiology, 2003, 12, 283-287.	0.6	19
123	Warfarin Dose Reduction vs Watchful Waiting for Mild Elevations in the International Normalized Ratio*. Chest, 2003, 123, 499-503.	0.8	30
124	Substitution of Generic Warfarin for Coumadin in an HMO Setting. Annals of Pharmacotherapy, 2002, 36, 764-768.	1.9	31
125	Seasonal control of warfarin therapy. American Journal of Medicine, 2001, 111, 332.	1.5	2
126	Warfarin Therapy for an Octogenarian Who Has Atrial Fibrillation. Annals of Internal Medicine, 2001, 134, 465.	3.9	53

Brian F Gage

#	Article	IF	CITATIONS
127	The Impact of the Introduction of a Rapid D-Dimer Assay on the Diagnostic Evaluation of Suspected Pulmonary Embolism. Archives of Internal Medicine, 2001, 161, 567.	3.8	58
128	Patient and physician satisfaction with a telephone-based anticoagulation service. Journal of General Internal Medicine, 2001, 16, 460-463.	2.6	66
129	Establishing and running an effective telephone-based anticoagulation service. Journal of Vascular Nursing, 2001, 19, 126-133.	0.7	17
130	Validation of Clinical Classification Schemes for Predicting Stroke. JAMA - Journal of the American Medical Association, 2001, 285, 2864.	7.4	4,383
131	Adverse Outcomes and Predictors of Underuse of Antithrombotic Therapy in Medicare Beneficiaries With Chronic Atrial Fibrillation. Stroke, 2000, 31, 822-827.	2.0	280
132	Management and dosing of warfarin therapy. American Journal of Medicine, 2000, 109, 481-488.	1.5	139
133	Criteria for Outpatient Management of Proximal Lower Extremity Deep Venous Thrombosis. Chest, 1999, 115, 972-979.	0.8	39
134	Cost-Effectiveness of Preference-Based Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation. Stroke, 1998, 29, 1083-1091.	2.0	96
135	Cost-effectiveness of Warfarin and Aspirin for Prophylaxis of Stroke in Patients With Nonvalvular Atrial Fibrillation, JAMA - Journal of the American Medical Association, 1995, 274, 1839	7.4	259